IGEM:MIT/2006/System brainstorming/Scent subprojects: Difference between revisions
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
introduce the minty fresh smelling coding region/enzyme into a genetically engineered strain of Streptococcus mutans bacteria | introduce the minty fresh smelling coding region/enzyme into a genetically engineered strain of Streptococcus mutans bacteria | ||
Streptococcus mutans, a bacterium that inhabits the human mouth, causes cavities by converting sugar into enamel-corroding lactic acid. Dr. Jeffrey D. Hillman of the University of Florida College of Dentistry in Gainesville has developed a genetically modified strain of the bug that doesn't make lactic acid, but is able to shoulder out competing bacteria. The new bacterium, dubbed BCS3-L1, could prevent cavities by colonizing the mouth and getting rid of its cavity-causing cousin. This new GM "good bug" was publicly announced in 2002 and experimental treatment has been successful in animals. Also it was approved for human trials by the FDA in 2004, and is currently in phase I of those trials. Funding has been secured and this new product is proposed to be on the market by 2008. | |||
p.s. : currently, the cavity industry supplies dentists with nearly half of their annual income (around 27 billion dollars). | p.s. : currently, the cavity industry supplies dentists with nearly half of their annual income (around 27 billion dollars). |
Revision as of 20:21, 5 June 2006
Subproject 1: idea/references (if you wanna check out):
IDEA:
introduce the minty fresh smelling coding region/enzyme into a genetically engineered strain of Streptococcus mutans bacteria
Streptococcus mutans, a bacterium that inhabits the human mouth, causes cavities by converting sugar into enamel-corroding lactic acid. Dr. Jeffrey D. Hillman of the University of Florida College of Dentistry in Gainesville has developed a genetically modified strain of the bug that doesn't make lactic acid, but is able to shoulder out competing bacteria. The new bacterium, dubbed BCS3-L1, could prevent cavities by colonizing the mouth and getting rid of its cavity-causing cousin. This new GM "good bug" was publicly announced in 2002 and experimental treatment has been successful in animals. Also it was approved for human trials by the FDA in 2004, and is currently in phase I of those trials. Funding has been secured and this new product is proposed to be on the market by 2008.
p.s. : currently, the cavity industry supplies dentists with nearly half of their annual income (around 27 billion dollars).
REFERENCES:
1. http://www.newscientist.com/article.ns?id=dn1941
2.http://www.sciencedaily.com/releases/2005/08/050814175146.htm
3. http://msnbc.msn.com/id/6629884
4. http://sec.edgar-online.com/2004/03/17/0001144204-04-003117/Section2.asp